Citius Oncology, Inc.
Citius Oncology, Inc. (CTOR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctor · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Citius Oncology, Inc. (CTOR) measures how much investors pay for each dollar of the company's trailing earnings. CTOR's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.42.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2022 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Citius Oncology, Inc.You CTOR | $74M | N/A | — | -$0.42 |
 Actuate Therapeutics Inc ACTU | $44M | N/A | — | -$1.06 |
 Applied Therapeutics, Inc. APLT | $15M | N/A | — | -$0.76 |
 Fate Therapeutics, Inc. FATE | $223M | N/A | — | -$1.15 |
 Forte Biosciences, Inc. FBRX | $218M | N/A | — | -$0.47 |
 LENSAR, Inc. LNSR | $68M | N/A | — | -$2.87 |
 Seres Therapeutics, Inc. MCRB | $61M | 23.14x | — | $0.64 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-0.34 | — | |
2024-09-30 FY2024 | — | $-0.30 | — | |
2023-09-30 FY2023 | — | $-0.14 | — | |
2022-09-30 FY2022 | — | $-0.12 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Citius Oncology, Inc. (CTOR) measures how much investors pay for each dollar of the company's trailing earnings. CTOR's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.42.
Frequently asked questions
CTOR pe ratio · 6 questionsCTOR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.80 and TTM EPS of -$0.42. Data sourced from Financial Modeling Prep via CTOR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Citius Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09